Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.

Australia Betacoronavirus / immunology COVID-19 Comorbidity Consensus Coronavirus Infections / epidemiology Drug Therapy Guideline Adherence Humans Infection Control / methods Leukemia, Lymphocytic, Chronic, B-Cell / immunology Lymphoma / immunology Multiple Myeloma / immunology New Zealand Pandemics / prevention & control Pneumonia, Viral / epidemiology Practice Guidelines as Topic Risk Assessment SARS-CoV-2 Salvage Therapy / methods Stem Cell Transplantation / methods

COVID-19 chronic lymphocytic leukaemia lymphoma myeloma

Journal

Internal medicine journal

ISSN: 1445-5994

Titre abrégé: Intern Med J

Pays: Australia

ID NLM: 101092952

Informations de publication

Date de publication:
06 2020

Historique:

received: 08 04 2020

revised: 15 04 2020

accepted: 15 04 2020

pubmed: 18 5 2020

medline: 27 6 2020

entrez: 17 5 2020

Statut: ppublish

Résumé

The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.

Identifiants

DOI: 10.1111/imj.14859 PMID: 32415723

pubmed: 32415723

doi: 10.1111/imj.14859

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

667-679

Informations de copyright

Références

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-13.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.

Fauci AS, Lane HC, Redfield RR. Covid-19-navigating the uncharted. N Engl J Med 2020; 382: 1268-9.

Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; 323: 1545-6.

Kim YJ, Lee ES, Lee YS. High mortality from viral pneumonia in patients with cancer. Infect Dis (Lond) 2019; 51: 502-9.

Chemaly RF, Vigil KJ, Saad M, Vilar-Compte D, Cornejo-Juarez P, Perez-Jimenez C et al. A multicenter study of pandemic influenza a (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 2012; 118: 4627-33.

Vilar-Compte D, Shah DP, Vanichanan J, Cornejo-Juarez P, Garcia-Horton A, Volkow P et al. Influenza in patients with hematological malignancies: experience at two comprehensive cancer centers. J Med Virol 2018; 90: 50-60.

Wingard JR. Influenza: preparedness for an inevitable 'emergency' for oncology and BMT units. J Natl Compr Canc Netw 2008; 6: 215-22.

Weinkove R, McQuilten Z, Adler J, Agar M, Blyth E, Cheng A et al. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust 2020 [cited 2020 Mar 25]. Available from URL:. https://www.mja.com.au/journal/2020/212/10/managing-haematology-and-oncology-patients-during-covid-19-pandemic-interim.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 2018; 36: 1443-53.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-4.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381: 1817-26.

Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 2020; 394: 2271-81.

Lamy T, Damaj G, Gyan E, Soubeyran P, Bouabdallah K, Cartron G et al. R-CHOP with or without radiotherapy in non-bulky limited-stage diffuse large B cell lymphoma (DLBCL): preliminary results of the prospective randomized phase III 02-03 trial from the Lysa/Goelams group. Blood 2014; 124: 393-3.

Persky DO, Li H, Stephens DM, Park SI, Bartlett NL, Swinnen LJ et al. PET-directed therapy for patients with limited-stage diffuse large B-cell lymphoma - results of intergroup Nctn study S1001. Blood 2019; 134: 349-9.

Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 2014; 166: 891-901.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303. J Clin Oncol 2019; 37: 1790-9.

Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P et al. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Adv 2019; 3: 2013-21.

Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR et al. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. Blood 2020. https://doi.org/10.1182/blood.2020006028.

Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 2014; 32: 3490-6.

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-90.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-5.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017; 130: 1800-8.

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020; 38: 155-65.

Chan EHL, Koh LP, Lee J, De Mel S, Jeyasekharan A, Liu X et al. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med 2019; 8: 4626-32.

Savage KJ, Yenson PR, Shenkier T, Klasa R, Villa D, Goktepe O et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 2012; 120: 303-3.

Hoelzer D, Walewski J, Dohner H, Viardot A, Hiddemann W, Spiekermann K et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 2014; 124: 3870-9.

Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med 2013; 369: 1915-25.

Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish lymphoma registry. Blood 2014; 124: 1570-7.

Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood 2010; 116: 3418-25.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study. Cancer 2019; 125: 1507-17.

Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516-22.

Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1110-7.

Chan EK, Fung S, Gospodarowicz M, Hodgson D, Wells W, Sun A et al. Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011; 81: e781-6.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa248.

Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma 2016; 57: 512-9.

Martinez-Calle N, Hartley S, Ahearne M, Kasenda B, Beech A, Knight H et al. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. Br J Haematol 2019; 184: 957-68.

Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 452-7.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 2018; 36: 2395-404.

Bachy E, Seymour JF, Feugier P, Offner F, López-Guillermo A, Belada D et al. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 2019; 37: 2815-24.

Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008; 19: 1327-30.

Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015; 372: 1598-607.

von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol 2012; 30: 907-13.

Andre MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2017; 35: 1786-94.

Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 943-52.

Mounier N, Brice P, Bologna S, Briere J, Gaillard I, Heczko M et al. ABVD (8 cycles) versus BEACOPP (4 escalated cycles >/= 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 2014; 25: 1622-8.

Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203-12.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet 2018; 390: 2790-802.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol 2019; 20: 202-15.

Johnson P, Federico M, Kirkwood A, Fossa A, Berkahn L, Carella A et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med 2016; 374: 2419-29.

Moskowitz AJ, Schoder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-Centre, phase 2 study. Lancet Oncol 2015; 16: 284-92.

Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665-70.

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood 2019; 134: 1144-53.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-9.

Sandhu S, Mackinlay N, Coyle L, Best G, Mulligan S. Detailed long-term follow up of treatment-naive chronic lymphocytic leukemia (CLL) patients in the Australasian leukemia and lymphoma group (ALLG) CLL5 trial; data on 17 (15% of Total cohort) patients from a single-institution. Blood 2015; 126: 5294-4.

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018; 19: 953-64.

Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010; 115: 3416-7.

Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N et al. Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia 2018; 32: 2495-518.

Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-99.

Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R et al. Bone marker-directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study. Clin Cancer Res 2016; 22: 1378-84.

Quach H, Prince M. Clinical Practice Guideline: Multiple Myeloma. Myeloma Australia 2019 [cited 2020 Apr 1). Available from URL: https://myeloma.org.au/wp-content/uploads/2019/10/myeloma_clinical_practice_guideline_oct19.pdf

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538-48.

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C et al. Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma. Bone Marrow Transplant 2018; 53: 1116-23.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S et al. Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial. J Clin Oncol 2019; 37: 589-97.

Larocca A, Salvini M, Gaidano G, Cascavilla N, Baldini L, Aglietta M et al. Sparing steroids in elderly intermediate-fit newly diagnosed multiple myeloma patients treated with a dose/schedule-adjusted Rd-R vs. continuous Rd: results of RV-MM-PI-0752 phase III randomized study. HemaSphere 2019; 3: 244.

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27-38.

Bringhen S, D'Agostino M, De Paoli L, Montefusco V, Liberati AM, Galieni P et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia 2018; 32: 979-85.

Gibbs SDJ, Mollee P. Clinical Practice Guideline: Systemic AL Amyloidosis. Myeloma Australia 2019 [cited 2020 Apr 7]. Available from URL: https://myeloma.org.au/wp-content/uploads/2019/10/MSAG_ATG_oct19.pdf

Ando Y, Hegenbart U, Kastritis E, Kumar SK, Milani P, Minnema MC, et al. International Society of Amyloidosis recommendations on the management of patients with systemic amyloidosis during the COVID-19 pandemic. International Society of Amyloidosis 2020 [cited 2020 Apr 7]. Available from URL: https://cms.cws.net/content/isaamyloidosis.org/files/ISA%20recommendations%20Covid-19%20v_%202_6%20final.pdf

Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol 2020; 189: 241-3.

Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S et al. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther 2017; 34: 2210-31.

Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol 2017; 4: e272-e82.

Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014; 10: CD003039.

Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1: CD004386.

Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14: 882-913.

Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect 2018; 76: 20-37.

Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M, Infectious diseases working Party et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2013; 92: 433-42.

Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C et al. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Intern Med J 2014; 44: 1350-63.

Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 1052-9.

Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2008; 4: CD006501.

Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Rev 2018; 32: 106-15.

Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UKGroup for Immunoglobulin Replacement Therapy in multiple myeloma. Lancet 1994; 343: 1059-63.

Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M et al. Response to pneumococcal vaccination in multiple myeloma. Cancer Med 2019; 8: 3822-30.

Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bjorkholm M, Hultcrantz M et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015; 100: 107-13.

Backhaus E, Berg S, Andersson R, Ockborn G, Malmstrom P, Dahl M et al. Epidemiology of invasive pneumococcal infections: manifestations, incidence and case fatality rate correlated to age, gender and risk factors. BMC Infect Dis 2016; 16: 367.

Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian "levels of evidence". BMC Med Res Methodol 2009; 9: 34.